Pathologic Mechanobiological Interactions Between Red Blood Cells and Endothelial Cells Directly Induce Vasculopathy in Iron Deficiency Anemia

2021 ◽  
Author(s):  
Christina Caruso ◽  
Meredith E. Fay ◽  
Xiaopo Cheng ◽  
Alan Y. Liu ◽  
Sunita I. Park ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Iron Deficiency ◽  
Red Blood Cells ◽  
Iron Deficiency Anemia ◽  
Blood Cells ◽  
Deficiency Anemia

CORRELATION OF GLYCATED HAEMOGLOBIN WITH SERUM IRON, FERRITIN AND TIBC IN IRON DEFICIENCY ANEMIA

2020 ◽  
Vol 4 (2) ◽  
Author(s):  
Manoj Naphade ◽  
Ranjeet Ambad
Keyword(s):  
Iron Deficiency ◽  
Red Blood Cells ◽  
Iron Deficiency Anemia ◽  
Blood Cells ◽  
Serum Iron ◽  
Ferritin Level ◽  
Deficiency Anemia ◽  
Case Group ◽  
Haematological Parameter ◽  
Detailed Medical History

Iron deficiency anemia is a common type of anemia — a condition in which blood lacks adequate healthy red blood cells. Red blood cells carry oxygen to the body's tissues. As the name implies, iron deficiency anemia is due to insufficient iron. HbA1c shows patient’s glycemic status of last 3 months. Some previous studies have been reported that iron deficiency anemia may increase the level of HbA1c. AIM: To assess the status of HbA1c in patients of iron deficiency anemia & correlate HbA1c level with Serum Iron, Ferritin level. MATERIALS AND METHODS: It is a cross sectional comparative study conducted in 1 yrs of duration. A total number of 60 subjects between the ages of 18 to 60 years were enrolled for the present study. Detailed medical history and relevant clinical examination data and written consent were obtained from all subjects by explaining the study procedure. RESULTS: Haematological parameter like Hb, MCV, MCH, HCT and RDW were showed significantly difference in iron deficiency case and   control groups. Total haemoglobin, MCV, MCH, HCT were significantly reduced in IDA case group whereas there is increase RDW level in case group as compare to control (p<0.001). CONCLUSION: There is negative correlation of HbA1c with Haemoglobin, Serum Iron and ferritin level whereas positive correlation is detected with TIBC. The correlation of HbA1c is found to be significant with serum iron and MCH. Keywords: Hb, MCV, MCH, HCT and RDW

scholarly journals Increased Formation of Early-Labeled Bilirubin in Rats with Iron Deficiency Anemia: Evidence for Ineffective Erythropoiesis

Blood ◽  
1969 ◽  
Vol 33 (6) ◽  
pp. 909-917 ◽  
Author(s):  
STEPHEN H. ROBINSON
Keyword(s):  
Iron Deficiency ◽  
Red Blood Cells ◽  
Iron Deficiency Anemia ◽  
Blood Cells ◽  
Iron Therapy ◽  
Deficiency Anemia ◽  
Bile Pigment ◽  
Ineffective Erythropoiesis ◽  
Acute Response

Abstract The production of early-labeled bilirubin and erythrocyte hemoglobin heme was measured in rats with iron deficiency anemia, using glycine-2-14C as precursor. The erythropoietic component of the early pigment fraction was significantly augmented and the formation of labeled hemoglobin depressed in the anemic animals, findings characteristic of ineffective erythropoiesis. By contrast, the hepatic component of early-labeled bilirubin was substantially enlarged during the acute response to iron therapy. These experiments illustrate that overproduction of bilirubin may originate from both erythropoietic and hepatic sources of the early-labeled fraction of bile pigment, as well as from hemolysis of circulating red blood cells.

Diagnosis of iron deficiency anemia using density-based fractionation of red blood cells

Lab on a Chip ◽  
2016 ◽  
Vol 16 (20) ◽  
pp. 3929-3939 ◽  
Author(s):  
Jonathan W. Hennek ◽  
Ashok A. Kumar ◽  
Alex B. Wiltschko ◽  
Matthew R. Patton ◽  
Si Yi Ryan Lee ◽  
...  
Keyword(s):  
Machine Learning ◽  
Iron Deficiency ◽  
Red Blood Cells ◽  
Iron Deficiency Anemia ◽  
Blood Cells ◽  
Point Of Care ◽  
Deficiency Anemia ◽  
Point Of Care Test

We have developed a new point-of-care test to diagnose iron deficiency anemia by eye or using machine learning.

scholarly journals Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy

2021 ◽  
pp. 1-6
Author(s):  
Ibrahim A. Abdelazim ◽  
Mohannad AbuFaza ◽  
Soud M. Al-Ajmi ◽  
Osama O. Amer ◽  
Svetlana Shikanova ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Red Blood Cells ◽  
Iron Deficiency Anemia ◽  
Blood Cells ◽  
Heme Iron ◽  
Post Treatment ◽  
Deficiency Anemia ◽  
Mean Corpuscular Hemoglobin ◽  
Ferrous Fumarate ◽  
Anemia During Pregnancy

OBJECTIVES: This study designed to compare the efficacy, and tolerability of heme-iron OptiFer® to ferrous fumarate in the treatment of iron deficiency anemia during pregnancy. STUDY DESIGN: Two hundred and thirty-four (234) women with iron deficiency anemia during pregnancy were included in this study; 121 women in the heme-iron OptiFer® group, and 113 women in the ferrous fumarate group. Women in the heme-iron OptiFer® group received OptiFer® tablets twice daily for ≥3 months then once daily as a maintenance dose. Women in the ferrous fumarate group received 350 mg oral ferrous fumarate once daily for ≥3 months. The pre-treatment ferritin, hemoglobin, red blood cells-mean corpuscular volume, and red blood cells-mean corpuscular hemoglobin were compared by the post-treatment values in the two studies. RESULTS: The post-treatment hemoglobin and ferritin were significantly high in the heme-iron OptiFer® group (11.2±7.1 gm/dL and 112.8±54.8 ug/l, respectively) compared to the ferrous fumarate group (10.9 ±5.1 and 89.9±43.3, respectively; p=0.0002 and p=0.006; respectively). The post-treatment red blood cells-mean corpuscular volume and red blood cells-mean corpuscular hemoglobin were significantly high in the heme-iron OptiFer® group (92.0±4.1 fl and 31.9±6.2 pg, respectively) compared to the ferrous fumarate group (87.7±2.9 and 28.5±4.7, respectively; p=0.0001 and p=0.001, respectively). The rates of poor compliance and gastrointestinal intolerance were significantly high in the ferrous fumarate group compared to the heme-iron OptiFer® group (12.4% and 19.5%, respectively versus 3.3% and 2.5%, respectively), (p=0.01 and p=0.0001, respectively). CONCLUSION: Heme-iron OptiFer® is an effective therapeutic option for the treatment of iron deficiency anemia during pregnancy with low side effects. heme-iron OptiFer® can be used in women who have low compliance, and/or gastrointestinal intolerance to conventional iron salts.

Sign in / Sign up

Export Citation Format

Share Document